-
M Bonini,
C Bachert,
C E Baena-Cagnani,
A Bedbrook,
J L Brozek,
G W Canonica,
A A Cruz,
W J Fokkens,
R Gerth van Wijk,
L Grouse, [......],
G K Scadding,
H J Schünemann,
D M Thomas,
M Triggiani,
A Yorgancioglu,
O M Yusuf,
T Zuberbier,
R Pawankar,
J Bousquet,
S Bonini
Current Opinion in Allergy and Clinical Immunology 12/2012; · 4.11 Impact Factor
-
J Bousquet,
H J Schünemann, B Samolinski,
P Demoly,
C E Baena-Cagnani,
C Bachert,
S Bonini,
L P Boulet,
P J Bousquet,
J L Brozek, [......],
M Wickman,
S Wöhrl,
J Wright,
B P Yawn,
P K Yiallouros,
H J Zar,
M E Zernotti,
N Zhong,
M Zidarn,
T Zuberbier
[show abstract]
[hide abstract]
ABSTRACT: Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified AR as mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children.
The Journal of allergy and clinical immunology 10/2012; · 9.17 Impact Factor
-
A Yorgancıoğlu,
C Özdemir,
Ö Kalaycı,
A F Kalyoncu,
C Bachert,
C E Baena-Cagnani,
T B Casale,
Y Z Chen,
A A Cruz,
P Demoly, [......],
Y Mohammad,
J Mullol,
K Ohta,
N G Papadopoulos,
R Pawankar, B Samolinski,
H J Schünemann,
O M Yusuf,
T Zuberbier,
J Bousquet
[show abstract]
[hide abstract]
ABSTRACT: Allergic rhinitis and asthma represent global health problems for all age groups. Asthma and rhinitis frequently co-exist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization (WHO) workshop in 1999 and was published in 2001. ARIA has reclassified allergic rhinitis as mild/moderate-severe and intermittent/persistent. This classification schema closely reflects the impact of allergic rhinitis on patients. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of allergic rhinitis and asthma co-morbidities based on GRADE (Grading of Recommendation, Assessment, Development and Evaluation). ARIA has been disseminated and implemented in over 50 countries of the world. In Turkey, it is important to make a record of ARIA achievements and to identify the still unmet clinical, research and implementation needs in order to strengthen the 2011 EU Priority on allergy and asthma in children.
Tuberkuloz ve toraks 03/2012; 60(1):92-7.
-
Prof Jean Bousquet,
J Bousquet,
J M Anto,
P Demoly,
H J Schünemann,
A Togias,
M Akdis,
C Auffray,
C Bachert,
T Bieber, [......],
M Wickman,
D Williams,
S Wöhrl,
J Wright,
A Yorgancioglu,
O M Yusuf,
H J Zar,
M E Zernotti,
M Zidarn,
N Zhong
[show abstract]
[hide abstract]
ABSTRACT: Abstract
Concepts of disease severity, activity, control and responsiveness
to treatment are linked but different. Severity refers to
the loss of function of the organs induced by the disease process
or to the occurrence of severe acute exacerbations. Severity
may vary over time and needs regular follow-up. Control
is the degree to which therapy goals are currently met.
These concepts have evolved over time for asthma in guidelines,
task forces or consensus meetings. The aim of this paper
is to generalize the approach of the uniform definition of severe
asthma presented to WHO for chronic allergic and associated
diseases (rhinitis, chronic rhinosinusitis, chronic urticaria
and atopic dermatitis) in order to have a uniform definition
of severity, control and risk, usable in most situations. It
is based on the appropriate diagnosis, availability and accessibility
of treatments, treatment responsiveness and associated
factors such as comorbidities and risk factors. This uniform
definition will allow a better definition of the phenotypes
of severe allergic (and related) diseases for clinical
practice, research (including epidemiology), public health
purposes, education and the discovery of novel therapies.
Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology 01/2012; · 2.83 Impact Factor
-
J Bousquet,
J M Anto,
P Demoly,
H J Schünemann,
A Togias,
M Akdis,
C Auffray,
C Bachert,
T Bieber,
P J Bousquet, [......],
D Williams,
S Wöhrl,
J Wright,
A Yorgancioglu,
O M Yusuf,
H J Zar,
M E Zernotti,
M Zidarn,
N Zhong,
T Zuberbier
[show abstract]
[hide abstract]
ABSTRACT: Concepts of disease severity, activity, control and responsiveness to treatment are linked but different. Severity refers to the loss of function of the organs induced by the disease process or to the occurrence of severe acute exacerbations. Severity may vary over time and needs regular follow-up. Control is the degree to which therapy goals are currently met. These concepts have evolved over time for asthma in guidelines, task forces or consensus meetings. The aim of this paper is to generalize the approach of the uniform definition of severe asthma presented to WHO for chronic allergic and associated diseases (rhinitis, chronic rhinosinusitis, chronic urticaria and atopic dermatitis) in order to have a uniform definition of severity, control and risk, usable in most situations. It is based on the appropriate diagnosis, availability and accessibility of treatments, treatment responsiveness and associated factors such as comorbidities and risk factors. This uniform definition will allow a better definition of the phenotypes of severe allergic (and related) diseases for clinical practice, research (including epidemiology), public health purposes, education and the discovery of novel therapies.
International Archives of Allergy and Immunology 01/2012; 158(3):216-31. · 2.40 Impact Factor
-
J Bousquet,
L Heinzerling,
C Bachert,
N G Papadopoulos,
P J Bousquet,
P G Burney,
G W Canonica,
K H Carlsen,
L Cox,
T Haahtela, [......],
B Rogala,
A Romano,
D Ryan,
P Schmid-Grendelmeier,
A Todo-Bom,
R Valenta,
S Woehrl,
O M Yusuf,
T Zuberbier,
P Demoly
[show abstract]
[hide abstract]
ABSTRACT: This pocket guide is the result of a consensus reached between members of the Global Allergy and Asthma European Network (GA(2) LEN) and Allergic Rhinitis and its Impact on Asthma (ARIA). The aim of the current pocket guide is to offer a comprehensive set of recommendations on the use of skin prick tests in allergic rhinitis-conjunctivitis and asthma in daily practice. This pocket guide is meant to give simple answers to the most frequent questions raised by practitioners in Europe, including 'practicing allergists', general practitioners and any other physicians with special interest in the management of allergic diseases. It is not a long or detailed scientific review of the topic. However, the recommendations in this pocket guide were compiled following an in-depth review of existing guidelines and publications, including the 1993 European Academy of Allergy and Clinical Immunology position paper, the 2001 ARIA document and the ARIA update 2008 (prepared in collaboration with GA(2) LEN). The recommendations cover skin test methodology and interpretation, allergen extracts to be used, as well as indications in a variety of settings including paediatrics and developing countries.
Allergy 11/2011; 67(1):18-24. · 6.27 Impact Factor
-
J. Bousquet,
H. J. Schünemann,
T. Zuberbier,
C. Bachert,
C. E. Baena-Cagnani,
P. J. Bousquet,
J. Brozek,
G. W. Canonica,
T. B. Casale,
P. Demoly, [......],
G. Viegi,
J. C. Virchow,
D. Y. Wang,
M. Wickman,
D. Williams,
B. P. Yawn,
H. J. Zar,
M. Zernotti,
N. Zhong,
In collaboration with the WHO Collaborating Center of Asthma and Rhinitis (Montpellier
[show abstract]
[hide abstract]
ABSTRACT: To cite this article: Bousquet J, Schünemann HJ, Zuberbier T, Bachert C, Baena-Cagnani CE, Bousquet PJ, Brozek J, Canonica GW, Casale TB, Demoly P, Gerth van Wijk R, Ohta K, Bateman ED, Calderon M, Cruz AA, Dolen WK, Haughney J, Lockey RF, Lötvall J, O’Byrne P, Spranger O, Togias A, Bonini S, Boulet LP, Camargos P, Carlsen KH, Chavannes NH, Delgado L, Durham SR, Fokkens WJ, Fonseca J, Haahtela T, Kalayci O, Kowalski ML, Larenas-Linnemann D, Li J, Mohammad Y, Mullol J, Naclerio R, O’Hehir RE, Papadopoulos N, Passalacqua G, Rabe KF, Pawankar R, Ryan D, Samolinski B, Simons FER, Valovirta E, Yorgancioglu A, Yusuf OM, Agache I, Aït-Khaled N, Annesi-Maesano I, Beghe B, Ben Kheder A, Blaiss MS, Boakye DA, Bouchard J, Burney PG, Busse WW, Chan-Yeung M, Chen Y, Chuchalin AG, Costa DJ, Custovic A, Dahl R, Denburg J, Douagui H, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Kaliner MA, Keith PK, Kim YY, Klossek JM, Kuna P, Le LT, Lemiere C, Lipworth B, Mahboub B, Malo JL, Marshall GD, Mavale-Manuel S, Meltzer EO, Morais-Almeida M, Motala C, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Ouedraogo S, Palkonen S, Popov TA, Price D, Rosado-Pinto J, Scadding GK, Sooronbaev TM, Stoloff SW, Toskala E, van Cauwenberge P, Vandenplas O, van Weel C, Viegi G, Virchow JC, Wang DY, Wickman M, Williams D, Yawn BP, Zar HJ, Zernotti M, Zhong N, In collaboration with the WHO Collaborating Center of Asthma and Rhinitis (Montpellier). Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. Allergy 2010; 65: 1212–1221.AbstractThe links between asthma and rhinitis are well characterized. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines stress the importance of these links and provide guidance for their prevention and treatment. Despite effective treatments being available, too few patients receive appropriate medical care for both diseases. Most patients with rhinitis and asthma consult primary care physicians and therefore these physicians are encouraged to understand and use ARIA guidelines. Patients should also be informed about these guidelines to raise their awareness of optimal care and increase control of the two related diseases. To apply these guidelines, clinicians and patients need to understand how and why the recommendations were made. The goal of the ARIA guidelines is to provide recommendations about the best management options for most patients in most situations. These recommendations should be based on the best available evidence. Making recommendations requires the assessment of the quality of available evidence, deciding on the balance between benefits and downsides, consideration of patients' values and preferences, and, if applicable, resource implications. Guidelines must be updated as new management options become available or important new evidence emerges. Transparent reporting of guidelines facilitates understanding and acceptance, but implementation strategies need to be improved.
Allergy 09/2010; 65(10):1212 - 1221. · 6.27 Impact Factor
-
J. Bousquet,
H. J. Schunemann,
T. Zuberbier,
C. Bachert,
C. E. Baena-Cagnani,
P. J. Bousquet,
J. Brozek,
G. W. Canonica,
T. B. Casale,
P. Demoly, [......],
C. van Weel,
G. Viegi,
J. C. Virchow,
D. Y. Wang,
M. Wickman,
D. Williams,
B. P. Yawn,
H. J. Zar,
M. Zernotti,
N. Zhong
[show abstract]
[hide abstract]
ABSTRACT: The links between asthma and rhinitis are well characterized. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines stress the importance of these links and provide guidance for their prevention and treatment. Despite effective treatments being available, too few patients receive appropriate medical care for both diseases. Most patients with rhinitis and asthma consult primary care physicians and therefore these physicians are encouraged to understand and use ARIA guidelines. Patients should also be informed about these guidelines to raise their awareness of optimal care and increase control of the two related diseases. To apply these guidelines, clinicians and patients need to understand how and why the recommendations were made. The goal of the ARIA guidelines is to provide recommendations about the best management options for most patients in most situations. These recommendations should be based on the best available evidence. Making recommendations requires the assessment of the quality of available evidence, deciding on the balance between benefits and downsides, consideration of patients' values and preferences, and, if applicable, resource implications. Guidelines must be updated as new management options become available or important new evidence emerges. Transparent reporting of guidelines facilitates understanding and acceptance, but implementation strategies need to be improved.
Allergy 65(10):1212-21. · 6.27 Impact Factor
